Your browser doesn't support javascript.
loading
Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant.
Reuschl, Ann-Kathrin; Thorne, Lucy G; Zuliani-Alvarez, Lorena; Bouhaddou, Mehdi; Obernier, Kirsten; Hiatt, Joseph; Soucheray, Margaret; Turner, Jane; Fabius, Jacqueline M; Nguyen, Gina T; Swaney, Danielle L; Rosales, Romel; White, Kris M; Avilés, Pablo; Kirby, Ilsa T; Melnyk, James E; Shi, Ying; Zhang, Ziyang; Shokat, Kevan M; García-Sastre, Adolfo; Jolly, Clare; Towers, Gregory J; Krogan, Nevan J.
Affiliation
  • Reuschl AK; Division of Infection and Immunity, University College London, London, WC1E 6BT, United Kingdom.
  • Thorne LG; Division of Infection and Immunity, University College London, London, WC1E 6BT, United Kingdom.
  • Zuliani-Alvarez L; Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
  • Bouhaddou M; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, 94158, USA.
  • Obernier K; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
  • Hiatt J; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.
  • Soucheray M; Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
  • Turner J; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, 94158, USA.
  • Fabius JM; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
  • Nguyen GT; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.
  • Swaney DL; Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
  • Rosales R; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, 94158, USA.
  • White KM; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
  • Avilés P; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.
  • Kirby IT; Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
  • Melnyk JE; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
  • Shi Y; Medical Scientist Training Program, University of California, San Francisco, CA 94143, USA.
  • Zhang Z; Department of Microbiology and Immunology, University of California, San Francisco, CA 94143, USA.
  • Shokat KM; Biomedical Sciences Graduate Program, University of California, San Francisco,CA 94143, USA.
  • García-Sastre A; Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG), San Francisco, CA 94158, USA.
  • Jolly C; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, 94158, USA.
  • Towers GJ; J. David Gladstone Institutes, San Francisco, CA 94158, USA.
  • Krogan NJ; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.
bioRxiv ; 2021 Feb 04.
Article de En | MEDLINE | ID: mdl-33501437
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: BioRxiv Année: 2021 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: BioRxiv Année: 2021 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: États-Unis d'Amérique